No cancer diagnosis should ever be ignored - even "slow-moving" prostate cancer. Find out how a PSMA PET scan can be an important tool for life-changing healthcare decisions. 

Take the survey to learn more

A PET scan is an imaging technique that allows doctors to look for disease inside the body. In order to identify specific types of disease, such as cancer, a specialized tracer material is injected during the scan.

Illuccix is an advanced imaging tracer that binds to prostate cancer cells. This imaging tracer is then detected with a PET scan to reveal prostate cancer. This allows a doctor to see exactly where prostate cancer cells are located in the body.

PSMA, or prostate-specific membrane antigen, is a type of protein highly expressed by prostate cancer cells. A PSMA PET scan uses a small amount of tracer material coupled with a PSMA-specific molecule that attaches to this protein. The scan lights up the proteins and shows your doctor where the prostate cancer cells are in the body.

Your medical team needs accurate information to make informed decisions when developing your care plan. With precision targeting, your doctor can recommend the most appropriate treatment option for your unique situation. 

Because Illuccix targets the specific proteins expressed by prostate cancer cells, it may be able to detect tumors more accurately than conventional imaging, even when PSA levels are low or when other scans are inconclusive.

Our team of patient education specialists is here to help! Click the button below to take the survey. If you qualify for a PSMA PET scan, we can help answer other common questions, like:

- What should I expect during a PSMA PET scan?
- Does insurance cover this procedure?
- Are there any side effects?

Prostate cancer is a slow-moving disease that can be difficult to trace accurately.

Getting an accurate picture early in the process is crucial for making informed treatment decisions.

A PSMA PET scan with Illuccix may be right for you if you:

• Have been diagnosed with recurrent or metastatic prostate cancer,
• Have elevated PSA levels, and
• Are interested in discussing with your doctor whether alternatives to conventional imaging may help guide your care plan

Learn more by taking a brief survey below.

Learn more about a PSMA PET scan with Illuccix . If your answers indicate that this scan may be a good fit for you, one of our patient education specialists will contact you with more information.

Not medical advice or guidance. For informational purposes only. Always consult with your physician or a licensed medical professional for questions about your health, a cancer diagnosis, or treatment plan.

ILLUCCIX® (kit for the preparation of gallium Ga-68 gozetotide, for injection) is a prescription radioactive diagnostic agent that is prepared by a healthcare provider, and, then, injected. It is used with a medical imaging procedure called Positron Emission Tomography (PET) of lesions identified as prostate-specific membrane antigen (PSMA) positive. ILLUCCIX is used in men with prostate cancer whose cancer may have spread to other parts of the body and may need initial therapy or whose cancer may have come back, based on elevated serum prostate-specific antigen (PSA) levels. ILLUCCIX is also approved to help your healthcare provider determine whether you are appropriate for a certain treatment that is a PSMA-directed therapy.

• There is a risk your PET scan image with ILLUCCIX may be misinterpreted. A negative image does not rule out presence of prostate cancer, and a positive image does not confirm presence of prostate cancer. The ILLUCCIX PET scan may be affected by other factors, like the presence of other tissue types, PSMA levels and site of disease. Your healthcare provider will consider other information to confirm prostate cancer and determine treatment.
•  ILLUCCIX involves exposure to small amounts of radioactivity, and long-term cumulative radiation exposure is associated with increased risk for cancer. Your healthcare provider will use safe handling techniques to minimize radiation exposure.
•  You should drink water to hydrate before the scan and urinate immediately before the procedure and as often as possible during the first hours after the procedure to help reduce radioactivity exposure.
•  The most common side effects of ILLUCCIX in clinical trials were fatigue, nausea, diarrhea, constipation, vomiting, and dizziness. These adverse reactions each typically occurred in ≤1.2% of patients in clinical trials.

The full Prescribing Information is available at www.ILLUCCIX.com.

You are encouraged to report negative side effects to Telix Pharmaceuticals (US) at 1-844-455-8638 (pharmacovigilance@telixpharma.com) or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

ILLUCCIX® (kit for the preparation of gallium Ga-68 gozetotide, for injection) is a prescription radioactive diagnostic agent that is prepared by a healthcare provider, and, then, injected. It is used with a medical imaging procedure called Positron Emission Tomography (PET) of lesions identified as prostate-specific membrane antigen (PSMA) positive. ILLUCCIX is used in men with prostate cancer whose cancer may have spread to other parts of the body and may need initial therapy or whose cancer may have come back, based on elevated serum prostate-specific antigen (PSA) levels. ILLUCCIX is also approved to help your healthcare provider determine whether you are appropriate for a certain treatment that is a PSMA-directed therapy.

• There is a risk your PET scan image with ILLUCCIX may be misinterpreted. A negative image does not rule out presence of prostate cancer, and a positive image does not confirm presence of prostate cancer. The ILLUCCIX PET scan may be affected by other factors, like the presence of other tissue types, PSMA levels and site of disease. Your healthcare provider will consider other information to confirm prostate cancer and determine treatment.
•  ILLUCCIX involves exposure to small amounts of radioactivity, and long-term cumulative radiation exposure is associated with increased risk for cancer. Your healthcare provider will use safe handling techniques to minimize radiation exposure.
•  You should drink water to hydrate before the scan and urinate immediately before the procedure and as often as possible during the first hours after the procedure to help reduce radioactivity exposure.
•  The most common side effects of ILLUCCIX in clinical trials were fatigue, nausea, diarrhea, constipation, vomiting, and dizziness. These adverse reactions each typically occurred in ≤1.2% of patients in clinical trials.

The full Prescribing Information is available at www.ILLUCCIX.com.

You are encouraged to report negative side effects to Telix Pharmaceuticals (US) at 1-844-455-8638 (pharmacovigilance@telixpharma.com) or to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Copyright © 2024. All rights reserved | Privacy Policy